+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Targeted Therapy Market by Product Type, Route Of Administration, End User - Global Forecast to 2030- Product Image
Targeted Therapy Market by Product Type, Route Of Administration, End User - Global Forecast to 2030- Product Image
Sale

Targeted Therapy Market by Product Type, Route Of Administration, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 181 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6017448
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Targeted Therapy Market grew from USD 67.16 billion in 2024 to USD 72.41 billion in 2025. It is expected to continue growing at a CAGR of 7.53%, reaching USD 103.84 billion by 2030.

Unlocking the Power of Targeted Cancer Therapies

Advancements in molecular biology and precision medicine have ushered in a new era for oncology and beyond, where therapies are designed to strike specific cellular targets rather than relying on broad-spectrum approaches. This shift marks a fundamental departure from traditional cytotoxic regimens, emphasizing personalized treatment pathways that optimize efficacy while reducing systemic toxicity. By harnessing the power of genetic profiling and biomarker-driven selection, stakeholders across the value chain can better align therapeutic innovations with patient needs, payor requirements, and regulatory imperatives. As the landscape continues to evolve, it becomes essential for executives to grasp the foundational principles of targeted therapy and recognize the forces propelling this dynamic segment toward unprecedented growth and clinical impact.

Shifting Paradigms in Therapeutic Innovation

Over the past decade, targeted therapy has undergone remarkable transformation, driven by breakthroughs in antibody engineering, small molecule design, and proteolytic targeting chimera (PROTAC) technology. What began as a focus on monoclonal antibodies has expanded to include complex constructs such as antibody-drug conjugates that deliver cytotoxic payloads with surgical precision, as well as novel protein degraders that redirect the cellular machinery to dismantle disease-driving proteins. Parallel innovations in formulation and delivery have enabled the shift from hospital-based intravenous regimens to more convenient oral and subcutaneous options, broadening patient access and adherence. These converging trends underscore how continuous innovation is reconfiguring competitive dynamics and redefining the human health continuum.

The Ripple Effect of US Tariffs on Therapeutic Supply Chains

The introduction of comprehensive US tariffs in 2025 has reverberated across global supply chains, impacting both the cost structure and availability of critical biologics and small molecules. Import duties on active pharmaceutical ingredients and finished formulations have led manufacturers to reassess sourcing strategies, accelerate onshore production efforts, and pursue alternative trade agreements to mitigate price volatility. Subsequently, margins of contract development and manufacturing organizations have been compressed, prompting strategic realignments and consolidation in the service provider ecosystem. Looking ahead, stakeholders must remain vigilant to evolving trade policies and potential retaliatory measures, ensuring that procurement flexibility and geographic diversification remain core to supply continuity planning.

Tailoring Strategies through Multidimensional Segmentation Insights

Product innovation in targeted therapy manifests across diverse modalities, each driven by unique mechanistic imperatives. Conjugated antibodies now leverage CD22 and HER2 specificity to amplify tumor cell killing while sparing healthy tissue. Meanwhile, monoclonal antibodies have matured through a spectrum of constructs, from chimeric to fully humanized formats, enhancing safety and reducing immunogenicity. At the frontier, molecular glues and PROTACs represent a paradigm shift in disease intervention by harnessing intracellular degradation pathways. Complementing this diversity, delivery routes have evolved beyond inpatient infusion to include patient-administered oral capsules and subcutaneous injections that promote self-care and reduce hospital burden. Furthermore, the ultimate impact of these innovations is reflected in the settings where therapies are dispensed, spanning home-based care environments, institutional hospital pharmacies, community retail outlets, and specialty clinics dedicated to complex disease management.

Decoding Regional Dynamics Impacting Market Uptake

Regional dynamics in targeted therapy adoption exhibit marked differentiation in regulatory frameworks, reimbursement landscapes, and innovation ecosystems. In the Americas, robust venture capital investment and pioneering clinical trial networks drive rapid market entry, supported by streamlined approval processes. Across Europe, the Middle East and Africa, harmonization efforts under the European Medicines Agency coexist with country-specific pricing negotiations, creating a tapestry of opportunities and challenges for market access teams. Meanwhile, Asia-Pacific markets illustrate a spectrum of maturity, from advanced biopharma hubs that rival Western capabilities to emerging economies prioritizing local manufacturing and capacity building. Collectively, these regions shape the competitive intensity, partnership models, and localized strategies that define success in the global targeted therapy arena.

Competitive Landscape Driving Innovation and Growth

The competitive landscape of targeted therapy is defined by a cadre of biopharma leaders and agile disruptors that continually expand the frontier of clinical innovation. These organizations invest heavily in R&D pipelines spanning antibody drug conjugates, checkpoint inhibitors, and novel small molecule platforms. Strategic alliances between established pharmaceutical giants and nimble biotech firms facilitate technology transfers, expedite development timelines, and enhance commercial scale. Simultaneously, service providers specializing in cell line development, high-throughput screening, and regulatory consulting play a pivotal role in de‐risking complex programs. Observing the collaborative networks, patent landscapes, and portfolio diversification strategies of these companies offers critical vantage into emergent value pools and competitive pressures.

Strategic Imperatives for Industry Stakeholders

To capitalize on the trajectory of targeted therapies, industry leaders must adopt a multi-pronged approach that aligns scientific ambition with commercial pragmatism. First, forging cross-sector partnerships can accelerate access to cutting-edge technologies while distributing investment risk. Second, integrating agile manufacturing models and modular production capabilities will bolster supply chain resilience in the face of trade policy fluctuations and material shortages. Third, embedding patient-centric support services and digital health solutions enhances adherence, optimizes outcomes, and strengthens payer negotiations. Finally, nurturing talent skilled in translational science and market access will ensure that organizational structures can adapt swiftly to evolving clinical and regulatory paradigms.

Rigorous Methodological Framework Underpinning Insights

This analysis is grounded in a rigorous, hybrid methodology that synthesizes insights from primary interviews with key opinion leaders, C-suite executives, and field specialists, alongside an expansive secondary research effort aggregating peer‐reviewed journals, regulatory filings, and corporate disclosures. Quantitative data were subjected to triangulation across multiple sources to validate consistency, while qualitative inputs underwent thematic coding to surface prevailing trends and strategic inflection points. Geographic, therapeutic, and technological segmentation frameworks were iteratively refined through expert workshops to ensure alignment with real‐world practice and market realities. The resulting report offers a holistic, evidence‐based perspective designed to inform critical decisions across R&D, commercial strategy, and policy engagement.

Synthesis of Market Dynamics and Strategic Outlook

In summary, the targeted therapy market stands at the confluence of scientific breakthrough and strategic complexity, presenting both unprecedented opportunities and multifaceted challenges. The maturation of diverse modalities-from antibody drug conjugates and monoclonal antibodies to protein degraders and small molecule inhibitors-underscores the need for nuanced segmentation and tailored go‐to‐market strategies. Concurrently, shifting trade policies, regional dynamics, and competitive collaborations demand proactive risk management and agile decision‐making. By synthesizing these insights, stakeholders can illuminate pathways to sustainable growth, enhanced patient outcomes, and resilient supply chains in an era defined by precision medicine.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Antibody Drug Conjugates
      • Cd22 Directed
      • Her2 Directed
    • Monoclonal Antibodies
      • Chimeric
      • Fully Human
      • Humanized
    • Protein Degraders
      • Molecular Glues
      • Protacs
    • Small Molecule Inhibitors
      • Parp Inhibitors
      • Proteasome Inhibitors
      • Tyrosine Kinase Inhibitors
  • Route Of Administration
    • Intravenous
    • Oral
    • Subcutaneous
  • End User
    • Home Care
    • Hospital Pharmacy
    • Retail Pharmacy
    • Specialty Clinic
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • AbbVie Inc.
  • Amgen Inc.
  • Johnson & Johnson
  • Gilead Sciences, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Targeted Therapy Market, by Product Type
8.1. Introduction
8.2. Antibody Drug Conjugates
8.2.1. Cd22 Directed
8.2.2. Her2 Directed
8.3. Monoclonal Antibodies
8.3.1. Chimeric
8.3.2. Fully Human
8.3.3. Humanized
8.4. Protein Degraders
8.4.1. Molecular Glues
8.4.2. Protacs
8.5. Small Molecule Inhibitors
8.5.1. Parp Inhibitors
8.5.2. Proteasome Inhibitors
8.5.3. Tyrosine Kinase Inhibitors
9. Targeted Therapy Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous
10. Targeted Therapy Market, by End User
10.1. Introduction
10.2. Home Care
10.3. Hospital Pharmacy
10.4. Retail Pharmacy
10.5. Specialty Clinic
11. Americas Targeted Therapy Market
11.1. Introduction
11.2. United States
11.3. Canada
11.4. Mexico
11.5. Brazil
11.6. Argentina
12. Europe, Middle East & Africa Targeted Therapy Market
12.1. Introduction
12.2. United Kingdom
12.3. Germany
12.4. France
12.5. Russia
12.6. Italy
12.7. Spain
12.8. United Arab Emirates
12.9. Saudi Arabia
12.10. South Africa
12.11. Denmark
12.12. Netherlands
12.13. Qatar
12.14. Finland
12.15. Sweden
12.16. Nigeria
12.17. Egypt
12.18. Turkey
12.19. Israel
12.20. Norway
12.21. Poland
12.22. Switzerland
13. Asia-Pacific Targeted Therapy Market
13.1. Introduction
13.2. China
13.3. India
13.4. Japan
13.5. Australia
13.6. South Korea
13.7. Indonesia
13.8. Thailand
13.9. Philippines
13.10. Malaysia
13.11. Singapore
13.12. Vietnam
13.13. Taiwan
14. Competitive Landscape
14.1. Market Share Analysis, 2024
14.2. FPNV Positioning Matrix, 2024
14.3. Competitive Analysis
14.3.1. F. Hoffmann-La Roche Ltd
14.3.2. Novartis AG
14.3.3. Pfizer Inc.
14.3.4. Merck & Co., Inc.
14.3.5. Bristol-Myers Squibb Company
14.3.6. AstraZeneca PLC
14.3.7. AbbVie Inc.
14.3.8. Amgen Inc.
14.3.9. Johnson & Johnson
14.3.10. Gilead Sciences, Inc.
15. ResearchAI
16. ResearchStatistics
17. ResearchContacts
18. ResearchArticles
19. Appendix
List of Figures
FIGURE 1. TARGETED THERAPY MARKET MULTI-CURRENCY
FIGURE 2. TARGETED THERAPY MARKET MULTI-LANGUAGE
FIGURE 3. TARGETED THERAPY MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL TARGETED THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TARGETED THERAPY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TARGETED THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES TARGETED THERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES TARGETED THERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. TARGETED THERAPY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. TARGETED THERAPY MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. TARGETED THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TARGETED THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TARGETED THERAPY MARKET SIZE, BY CD22 DIRECTED, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TARGETED THERAPY MARKET SIZE, BY HER2 DIRECTED, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TARGETED THERAPY MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TARGETED THERAPY MARKET SIZE, BY FULLY HUMAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TARGETED THERAPY MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TARGETED THERAPY MARKET SIZE, BY MOLECULAR GLUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTACS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TARGETED THERAPY MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TARGETED THERAPY MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TARGETED THERAPY MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL TARGETED THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES TARGETED THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 50. CANADA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 51. CANADA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 52. CANADA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 53. CANADA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 54. CANADA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 55. CANADA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. CANADA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. MEXICO TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 58. MEXICO TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 59. MEXICO TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 60. MEXICO TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 61. MEXICO TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 62. MEXICO TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. MEXICO TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 86. UNITED KINGDOM TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 87. UNITED KINGDOM TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 88. UNITED KINGDOM TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 89. UNITED KINGDOM TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 90. UNITED KINGDOM TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 91. UNITED KINGDOM TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. UNITED KINGDOM TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. GERMANY TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 94. GERMANY TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 95. GERMANY TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 96. GERMANY TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 97. GERMANY TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 98. GERMANY TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. GERMANY TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. FRANCE TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 101. FRANCE TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 102. FRANCE TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 103. FRANCE TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 104. FRANCE TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 105. FRANCE TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. FRANCE TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. RUSSIA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 108. RUSSIA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 109. RUSSIA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 110. RUSSIA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 111. RUSSIA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 112. RUSSIA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. RUSSIA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. ITALY TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 115. ITALY TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 116. ITALY TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 117. ITALY TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 118. ITALY TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 119. ITALY TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. ITALY TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. SPAIN TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 122. SPAIN TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 123. SPAIN TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 124. SPAIN TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 125. SPAIN TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 126. SPAIN TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. SPAIN TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. UNITED ARAB EMIRATES TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 129. UNITED ARAB EMIRATES TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 130. UNITED ARAB EMIRATES TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 131. UNITED ARAB EMIRATES TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 132. UNITED ARAB EMIRATES TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 133. UNITED ARAB EMIRATES TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. UNITED ARAB EMIRATES TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. SAUDI ARABIA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 136. SAUDI ARABIA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 137. SAUDI ARABIA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 138. SAUDI ARABIA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 139. SAUDI ARABIA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 140. SAUDI ARABIA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. SAUDI ARABIA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. SOUTH AFRICA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 143. SOUTH AFRICA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 144. SOUTH AFRICA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 145. SOUTH AFRICA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 146. SOUTH AFRICA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 147. SOUTH AFRICA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. SOUTH AFRICA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. DENMARK TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 150. DENMARK TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 151. DENMARK TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 152. DENMARK TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 153. DENMARK TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 154. DENMARK TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. DENMARK TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. NETHERLANDS TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 157. NETHERLANDS TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 158. NETHERLANDS TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 159. NETHERLANDS TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 160. NETHERLANDS TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 161. NETHERLANDS TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 162. NETHERLANDS TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. QATAR TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 164. QATAR TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 165. QATAR TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 166. QATAR TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 167. QATAR TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 168. QATAR TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. QATAR TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. FINLAND TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 171. FINLAND TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 172. FINLAND TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 173. FINLAND TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 174. FINLAND TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 175. FINLAND TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 176. FINLAND TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. SWEDEN TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 178. SWEDEN TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 179. SWEDEN TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 180. SWEDEN TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 181. SWEDEN TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 182. SWEDEN TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. SWEDEN TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. NIGERIA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 185. NIGERIA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 186. NIGERIA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 187. NIGERIA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 188. NIGERIA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 189. NIGERIA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. NIGERIA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. EGYPT TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 192. EGYPT TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 193. EGYPT TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 194. EGYPT TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 195. EGYPT TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 196. EGYPT TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 197. EGYPT TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. TURKEY TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 199. TURKEY TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 200. TURKEY TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 201. TURKEY TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 202. TURKEY TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 203. TURKEY TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. TURKEY TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 205. ISRAEL TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 206. ISRAEL TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 207. ISRAEL TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 208. ISRAEL TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 209. ISRAEL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 210. ISRAEL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. ISRAEL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 212. NORWAY TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 213. NORWAY TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 214. NORWAY TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 215. NORWAY TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 216. NORWAY TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 217. NORWAY TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 218. NORWAY TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. POLAND TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 220. POLAND TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 221. POLAND TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 222. POLAND TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 223. POLAND TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 224. POLAND TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. POLAND TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. SWITZERLAND TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 227. SWITZERLAND TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 228. SWITZERLAND TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 229. SWITZERLAND TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 230. SWITZERLAND TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 231. SWITZERLAND TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 232. SWITZERLAND TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 239. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 241. CHINA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 242. CHINA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 243. CHINA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 244. CHINA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 245. CHINA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 246. CHINA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 247. CHINA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. INDIA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 249. INDIA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 250. INDIA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 251. INDIA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 252. INDIA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 253. INDIA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. INDIA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 255. JAPAN TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 256. JAPAN TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 257. JAPAN TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 258. JAPAN TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 259. JAPAN TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 260. JAPAN TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 261. JAPAN TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. AUSTRALIA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 263. AUSTRALIA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 264. AUSTRALIA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 265. AUSTRALIA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 266. AUSTRALIA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 267. AUSTRALIA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. AUSTRALIA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. SOUTH KOREA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 270. SOUTH KOREA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 271. SOUTH KOREA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 272. SOUTH KOREA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 273. SOUTH KOREA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 274. SOUTH KOREA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 275. SOUTH KOREA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 276. INDONESIA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 277. INDONESIA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 278. INDONESIA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 279. INDONESIA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 280. INDONESIA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 281. INDONESIA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 282. INDONESIA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 283. THAILAND TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 284. THAILAND TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 285. THAILAND TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 286. THAILAND TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 287. THAILAND TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 288. THAILAND TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 289. THAILAND TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 290. PHILIPPINES TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 291. PHILIPPINES TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 292. PHILIPPINES TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 293. PHILIPPINES TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 294. PHILIPPINES TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 295. PHILIPPINES TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 296. PHILIPPINES TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 297. MALAYSIA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 298. MALAYSIA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 299. MALAYSIA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 300. MALAYSIA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 301. MALAYSIA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 302. MALAYSIA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 303. MALAYSIA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 304. SINGAPORE TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 305. SINGAPORE TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 306. SINGAPORE TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 307. SINGAPORE TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 308. SINGAPORE TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 309. SINGAPORE TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 310. SINGAPORE TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 311. VIETNAM TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 312. VIETNAM TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 313. VIETNAM TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 314. VIETNAM TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 315. VIETNAM TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 316. VIETNAM TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 317. VIETNAM TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 318. TAIWAN TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 319. TAIWAN TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 320. TAIWAN TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 321. TAIWAN TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2030 (USD MILLION)
TABLE 322. TAIWAN TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 323. TAIWAN TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 324. TAIWAN TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 325. TARGETED THERAPY MARKET SHARE, BY KEY PLAYER, 2024
TABLE 326. TARGETED THERAPY MARKET, FPNV POSITIONING MATRIX, 2024

Companies Mentioned

The companies profiled in this Targeted Therapy market report include:
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • AbbVie Inc.
  • Amgen Inc.
  • Johnson & Johnson
  • Gilead Sciences, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages181
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 72.41 Billion
Forecasted Market Value ( USD ) by 2030 $ 103.84 Billion
Compound Annual Growth Rate7.5%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Dual Targeted Therapy Market by Therapy Type, Indication, Line of Therapy, Route of Administration, End User, Distribution Channel, Mechanism of Action - Global Forecast to 2030 - Product Image

Dual Targeted Therapy Market by Therapy Type, Indication, Line of Therapy, Route of Administration, End User, Distribution Channel, Mechanism of Action - Global Forecast to 2030

  • Report
  • 188 Pages
  • Global
From
Targeted Therapy Drugs for Melanoma Market by Mechanism Of Action, Route Of Administration, Treatment Line, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Targeted Therapy Drugs for Melanoma Market by Mechanism Of Action, Route Of Administration, Treatment Line, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 181 Pages
  • Global
From
Stomach Cancer Treatment Market Size, Share & Trends Analysis Report By Treatment Type, By Disease Indication, By Route Of Administration, By Drug Class, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Stomach Cancer Treatment Market Size, Share & Trends Analysis Report By Treatment Type, By Disease Indication, By Route Of Administration, By Drug Class, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
KRAS Inhibitors - Market Size, Target Population, Competitive Landscape & Market Forecast - 2034 - Product Image

KRAS Inhibitors - Market Size, Target Population, Competitive Landscape & Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Precision Oncology Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Precision Oncology Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.